The story appears in The Sacremento Bee, under the heading, Inaugural Dr. Guislain Award – “Breaking the Chains of Stigma” Makes Global Call for Nominations.
You know when Jenssen Research and Development, the folks who brought the world the atypical neuroleptic drug Risperidal, partners with a Belgium museum to present an “anti-stigma” award all is not up and above board.
The inaugural Dr. Guislain Award – “Breaking the Chains of Stigma” – and call for nominations is announced today by Museum Dr. Guislain in Ghent, Belgium, with support from Janssen Research & Development, LLC (“Janssen”). The $50,000 award will honor an individual, project or organization that has made an exceptional contribution to reducing the stigma associated with mental illness. Nominations can be submitted at http://www.drguislainaward.org, and will be accepted until August 4, 2012.
I see, in this case, $50,000 going out for drug promotion and sales as I don’t think they’d give this award to anybody who bashed their company or its product. Opposition to stigma has become a ploy used on behalf of biological psychiatry for promoting the notion of chronic psychiatric disability, and the selling of pharmaceuticals that goes along with that notion…
“Museum Dr. Guislain is very pleased to honor the memory of Dr. Guislain through the creation of this award,” said Brother Rene Stockman, general manager of the Museum Dr. Guislain. “In recognizing the important contributions of individuals and organizations who have helped to reduce the stigma associated with mental illness, we both acknowledge Dr. Guislain’s legacy and demonstrate the continuing need to educate the general public on harmful effects of social exclusion faced by many with mental illness.”
Wow, and they haven’t made much of a dent in “stigma” since 1860, the year of Dr. Guislain’s death? Funny, It says nothing here about the harmful effects of debilitating and health destroying drugs. One thing though, we can’t blame Dr. Guislain for neuroleptic drugs because he died a few years before they became the fashionable treatment they are today. The use of these drugs as a psychiatric treatment only started around about 1955 or so.
Conflict of interest is conflict of interest, and I’m gagging on the reek of conflict of interest in this piece. I’ve always had qualms about the slant history takes, too, when too many views are not represented. I hope the museum does a better job at presenting the past than it does at choosing its friends in the moment. Histories are not, to paraphrase a saying, written by the winners, histories are written by the survivors.
Filed under: Biological Psychiatry, Brain Damage, Conflict of Interest, Discrimination, Disinformation, Human Rights, Media, Mental Health Care, Oppression, Pharmaceutical Company, Psychiatric Drugs, psychiatric survivor